Amgen Inc. (NASDAQ: AMGN) announced that the U.S. FDA approved Uplizna (inebilizumab-cdon) for adult patients with anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis (gMG), marking the drug’s third approved indication.
Contents
Regulatory Milestone
| Item | Details |
|---|---|
| Approval Date | 11 Dec 2025 |
| Agency | U.S. FDA |
| Product | Uplizna (inebilizumab-cdon) |
| New Indication | gMG patients with anti-AChR or anti-MuSK antibodies |
| Mechanism | CD19 B cell depleting antibody |
| Dosing | 300 mg IV infusion every 6 months |
| Innovation | Third indication for Uplizna; first CD19-directed therapy for MuSK-positive gMG |
Clinical Evidence & Safety Profile
| Prior Indications | Approval Date | Population |
|---|---|---|
| NMOSD (AQP4‑positive) | June 2020 | Neuromyelitis optica spectrum disorder |
| IgG4‑RD | April 2025 | Immunoglobulin G4‑related disease |
| gMG (AChR/MuSK‑positive) | Dec 2025 | ~85% of generalized myasthenia gravis patients |
Safety: Consistent with established profile; infusion reactions managed with premedication.
Market Opportunity & Competitive Landscape
| Metric | Value | Context |
|---|---|---|
| US gMG Prevalence | 20,000‑40,000 patients | ~85% are AChR/MuSK‑positive |
| US gMG Market Size | $1.2 billion (2025) | Dominated by Soliris, Vyvgart, and Ultomiris |
| Uplizna Peak US Sales (gMG) | $300‑500 million by 2029 | 15‑20% market share in gMG segment |
| Competitive Advantage | CD19 depletion offers broad B‑cell knockdown | Differentiated vs. FcRn blockers |
| Global Expansion | Potential EU/Japan filings for gMG in 2026‑2027 | Expands beyond US market |
Licensing History & China Rights
| Timeline | Event |
|---|---|
| May 2019 | Hansoh Pharma (HKG: 3692) licenses inebilizumab from Viela Bio for mainland China, Hong Kong, Macau |
| 2021 | Viela Bio acquired by Horizon Therapeutics |
| 2023 | Horizon acquired by Amgen; rights transfer complete |
| Expected Filing | Hansoh to submit gMG NDA in China by 2026 |
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Uplizna’s market penetration, competitive positioning, and global expansion. Actual results may differ due to pricing negotiations, payer coverage decisions, and competitive responses from FcRn and complement inhibitors.-Fineline Info & Tech
